Does CNTA pay dividends?

CNTA (CNTA) has a dividend payment track record. See the CNTA dividend history page for its current payment status, yield, and streaks.

CNTA (CNTA)

Official site

BIOTECHNOLOGY

$40.50

+0.00 (+0.00%)

Last updated: Jun 25, 2026 at 5:00 PM ET

Earnings

Performance (10Y)

Beat Rate

57%(12/21)

Avg Surprise

+4.54%

Upcoming Estimates

Jun 30, 2026

EPS Consensus$-0.38

Range$-0.41 - $-0.30

5 analysts

EPS Revisions

30d

EPS Estimate Drift

90d ago$-0.39-3.6%

60d ago$-0.53-40.2%

30d ago$-0.40-6.7%

7d ago$-0.40-6.7%

Current$-0.38

Revenue Consensus

Range$0 - $0

6 analysts

Sep 30, 2026

EPS Consensus$-0.39

Range$-0.42 - $-0.31

5 analysts

EPS Revisions

30d

EPS Estimate Drift

90d ago$-0.40-3.4%

60d ago$-0.55-41.0%

30d ago$-0.42-6.8%

7d ago$-0.42-6.8%

Current$-0.39

Revenue Consensus

Range$0 - $0

6 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.47	$-0.63 - $-0.42	-	-	2	-	-
Sep 30, 2026Sep 26EST	-	$-0.39	$-0.42 - $-0.31	-	-	5	2 1 30d	-
Jun 30, 2026Jun 26EST	-	$-0.38	$-0.41 - $-0.30	-	-	5	2 1 30d	-
Mar 31, 2026Mar 26	$-0.52	$-0.38	$-0.51 - $-0.35	-36.84%	Miss	5	2 1 30d	-160.0%
Dec 31, 2025Dec 25	$-0.48	$-0.38	$-0.41 - $-0.32	-24.90%	Miss	8	-	-41.2%
Sep 30, 2025Sep 25	$-0.41	$-0.39	$-0.44 - $-0.32	-5.13%	Miss	9	0 3 30d	-10.8%
Jun 30, 2025Jun 25	$-0.38	$-0.35	$-0.37 - $-0.30	-8.57%	Miss	6	No revisions (30d)	+5.0%
Mar 31, 2025Mar 25	$-0.20	$-0.35	$-0.39 - $-0.31	+42.86%	Beat	2	1 1 30d	+47.4%
Dec 31, 2024Dec 24	$-0.34	$-0.38	$-0.40 - $-0.31	+10.53%	Beat	4	4 0 30d	+10.5%
Sep 30, 2024Sep 24	$-0.37	$-0.42	$-0.44 - $-0.36	+11.90%	Beat	6	No revisions (30d)	+7.5%
Jun 30, 2024Jun 24	$-0.40	$-0.38	$-0.44 - $-0.33	-5.26%	Miss	5	No revisions (30d)	-53.8%
Mar 31, 2024Mar 24	$-0.38	$-0.41	$-0.44 - $-0.40	+7.32%	Beat	3	No revisions (30d)	+28.3%
Dec 31, 2023Dec 23	$-0.38	$-0.44	$-0.60 - $-0.37	+13.64%	Beat	4	No revisions (30d)	+15.6%
Sep 30, 2023Sep 23	$-0.40	$-0.46	$-0.59 - $-0.45	+13.04%	Beat	4	No revisions (30d)	+29.8%
Jun 30, 2023Jun 23	$-0.26	$-0.43	$-0.54 - $-0.40	+39.53%	Beat	5	No revisions (30d)	+62.3%
Mar 31, 2023Mar 23	$-0.53	$-0.41	$-0.46 - $-0.36	-29.27%	Miss	3	No revisions (30d)	+11.7%
Dec 31, 2022Dec 22	$-0.45	$-0.48	$-0.51 - $-0.44	+6.25%	Beat	3	No revisions (30d)	+33.8%
Sep 30, 2022Sep 22	$-0.57	$-0.56	$-0.61 - $-0.52	-1.79%	Miss	2	No revisions (30d)	-26.7%
Jun 30, 2022Jun 22	$-0.69	$-0.57	$-0.57 - $-0.57	-21.05%	Miss	2	1 0 30d	-6.2%
Mar 31, 2022Mar 22	$-0.60	$-0.70	$-0.71 - $-0.67	+14.29%	Beat	3	No revisions (30d)	-400.0%
Dec 31, 2021Dec 21	$-0.68	$-0.60	$-0.66 - $-0.54	-13.33%	Miss	3	No revisions (30d)	+86.3%
Sep 30, 2021Sep 21	$-0.45	$-0.55	$-0.73 - $-0.46	+18.18%	Beat	3	No revisions (30d)	-2880.1%
Jun 30, 2021Jun 21	$-0.65	$-0.66	$-0.66 - $-0.66	+1.52%	Beat	1	No revisions (30d)	-3010.0%
Mar 31, 2021Mar 21	$-0.12	N/A	-	+62.50%	Beat	1	No revisions (30d)	-324.0%
Dec 31, 2020Dec 20	$-4.97	$0.00	-	N/A	Miss	-	-	-
Sep 30, 2020Sep 20	$-0.02	N/A	-	N/A	Beat	-	-	-
Jun 30, 2020Jun 20	$-0.02	N/A	-	N/A	Beat	-	-	-
Mar 31, 2020Mar 20	$-0.03	N/A	-	N/A	Beat	-	-	-

Dividends

Dividend Metrics

Yield0.00%

Annual/Share$0.00

FrequencyIrregular

Pay MonthsJun

Key Metrics

Valuation
P/E Ratio	N/A	EV/EBITDA	N/A
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	N/A	Operating Margin	N/A
ROE	N/A	ROIC	N/A
Financial Health
Debt/Equity	N/A	Interest Coverage	N/A
Current Ratio	N/A	Quick Ratio	N/A
Trading Statistics
Beta	N/A	Avg Volume	N/A
52-Week High	N/A	52-Week Low	N/A

Technical Indicators Dashboard

Moving Averages

SMA 10$40.06

SMA 20$39.92

SMA 50$39.72

SMA 200$29.44

EMA 10$40.16

EMA 20$39.96

EMA 50$38.61

EMA 200$30.48

MACD

Line: 0.30Signal: 0.28Hist: 0.02

ADX

ADX: 45.5+DI: 35.9-DI: 7.2

Aroon & PSAR

Aroon Up92.0

Aroon Down56.0

PSAR$39.68

Bollinger Bands

Upper Band$40.47

Lower Band$39.36

%B Position280%(Upper)

Band Width1.02

RSI (14-Day)

Overbought

78.2

Momentum Oscillators

Stoch %K93.9

Stoch %D94.8

Williams %R-6.1

ROC (10d)2.0%

Momentum0.81

CCI (20d)207.0

MFI (14d)80.6

Volatility Measures

ATR (14d)$0.20(0.5%)

StdDev (20d)0.28

Hist Vol4.2%(Low)

Volume Flow

VWAP$40.50

OBV89.0M

AD Line15.1M

CMF (20d)0.478

Volume Metrics

Avg Vol (20d)2.2M

Vol RatioN/A

VWMA (20d)$40.03

Pivot Points

R3$40.50

R2$40.50

R1$40.50

Pivot Point$40.50

S1$40.50

S2$40.50

S3$40.50

Advanced Oscillators

TSI42.41

Ultimate Osc79.3

KST8.74

Financial Data

Quarter	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023
Total Revenue	$0	$0	$0	$0	$15.00M	$0	$0	$0	$0	$6.85M	$0	$0
Cost of Revenue	$238,599	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Gross Profit	$-238,599	$0	$0	$0	$15.00M	$0	$0	$0	$0	$6.85M	$0	$0

Operating Expenses	$79.77M	$68.47M	$53.79M	$54.65M	$45.78M	$74.58M	$46.41M	$43.98M	$36.09M	$42.03M	$40.21M	$47.02M
R&D	$59.89M	$54.48M	$41.56M	$42.74M	$33.44M	$60.87M	$33.90M	$32.81M	$22.65M	$29.72M	$28.19M	$33.67M
SG&A	$19.88M	$13.99M	$12.23M	$11.91M	$12.33M	$13.71M	$12.50M	$11.16M	$13.44M	$12.31M	$12.02M	$13.35M
Operating Income	$-79,773,000	$-68,472,000	$-53,790,000	$-54,653,000	$-30,777,000	$-74,580,000	$-46,405,000	$-43,980,000	$-36,090,000	$-35,178,000	$-40,209,000	$-47,019,000

Interest Income	$5.14M	$4.49M	$3.77M	$4.38M	$7.89M	$4.84M	$3.34M	$3.24M	$2.59M	$2.93M	$2.95M	$2.06M
Interest Expense	$2.73M	$2.81M	$2.89M	$2.88M	$2.88M	$2.48M	$2.56M	$2.52M	$2.53M	$2.57M	$2.54M	$2.45M
Income Before Tax	$-78,391,000	$-66,685,000	$-54,725,000	$-49,565,000	$-24,738,000	$-110,279,000	$-41,958,000	$-43,111,000	$-37,565,000	$-35,693,000	$-41,474,000	$-48,937,000
Income Tax Expense	$850,000	$-522,000	$166,000	$778,000	$1.40M	$1.05M	$608,000	$705,000	$481,000	$1.14M	$-2,826,000	$-24,051,000

Net Income	$-79,241,000	$-66,163,000	$-54,891,000	$-50,343,000	$-26,135,000	$-111,329,000	$-42,566,000	$-43,816,000	$-38,046,000	$-36,837,000	$-38,648,000	$-24,886,000

EBITDA	$-75,425,979	$-87,074,000	$-51,598,000	$-46,455,000	$-21,644,000	$-107,570,000	$-39,165,000	$-40,350,000	$-34,796,000	$-32,877,000	$-38,695,000	$-46,250,000
EBIT	$-75,664,578	$-87,315,000	$-51,835,000	$-46,681,000	$-21,861,000	$-107,800,000	$-39,401,000	$-40,586,000	$-35,036,000	$-33,123,000	$-38,933,000	$-46,487,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about CNTA

News

Centessa Deadline Alert

Faruqi & Faruqi, LLP is investigating potential claims against Centessa Pharmaceuticals plc (NASDAQ: CNTA) and reminds investors of the November 28, 2022, deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Centessa made false and misleading statements regarding its drug candidates lixivaptan and ZF874, leading to significant stock price declines after safety issues and development discontinuations were announced. Investors who suffered losses exceeding $100,000 are encouraged to contact the law firm to discuss their legal options.

TMX Newsfile•Aug 5, 2026 12:48 AM8/5/26•

Bearish

Centessa Pharmaceuticals (NASDAQ: CNTA) Medicxi group now reports 0% ownership

An amended Schedule 13G filing reveals that the Medicxi group, comprising several affiliated investment entities, now reports zero beneficial ownership of Centessa Pharmaceuticals plc Ordinary Shares. As of June 30, 2026, the Medicxi Funds collectively own 0.0% of Centessa's outstanding shares, indicating they no longer hold voting or dispositive power over any shares. The filing was executed on August 4, 2026, by Francois Chesnay on behalf of the Reporting Persons.

Stock Titan•Aug 4, 2026 4:11 PM8/4/26•

Somewhat-Bearish

Centessa Deadline Alert

Faruqi & Faruqi, LLP is investigating potential securities claims against Centessa Pharmaceuticals plc (NASDAQ: CNTA) and reminds investors of the November 28, 2022 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Centessa made materially false and misleading statements regarding its business, operations, and prospects, specifically concerning the safety and commercial viability of its drug candidates lixivaptan and ZF874, leading to significant stock price drops. Investors who suffered losses exceeding $100,000 are encouraged to contact Faruqi & Faruqi to discuss their legal options.

TMX Newsfile•Aug 4, 2026 3:17 PM8/4/26•

Bearish

Centessa Pharmaceuticals PLC ADR Revenue Breakdown – MUN:260

Centessa Pharmaceuticals PLC ADR (MUN:260) generated 12.77 million EUR in revenue last year, primarily from its Clinical-stage Pharmaceutical segment. This segment contributed the entire revenue amount, which was up from 6.21 million EUR the previous year. The United Kingdom was the sole geographic contributor to this revenue.

TradingView•Aug 1, 2026 9:40 AM8/1/26•

Somewhat-Bullish

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

Eli Lilly and Company announced a definitive agreement to acquire Centessa Pharmaceuticals for an upfront cash consideration of approximately $6.3 billion, plus potential contingent value rights of up to $1.5 billion. Centessa specializes in OX2R agonists for sleep-wake disorders, with its lead candidate cleminorexton showing promise in Phase 2a studies. This acquisition is expected to significantly expand Lilly's neuroscience portfolio and capabilities in sleep medicine.

Eli Lilly and Company•Jul 22, 2026 1:10 PM7/22/26•

Bullish

Frequently Asked Questions About CNTA

Does CNTA pay dividends?: CNTA (CNTA) has a dividend payment track record. See the CNTA dividend history page for its current payment status, yield, and streaks.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In